Developing biomarker-specific end points in lung cancer clinical trials.
about
Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNARetroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types.Evaluation of Cross-Calibrated 68Ge/68Ga Phantoms for Assessing PET/CT Measurement Bias in Oncology Imaging for Single- and Multicenter TrialsPrognostic value and molecular correlates of a CT image-based quantitative pleural contact index in early stage NSCLC.Point of care assessment of melanoma tumor signaling and metastatic burden from μNMR analysis of tumor fine needle aspirates and peripheral blood.New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.Biologic Evaluation of Diabetes and Local Recurrence in Non-Small Cell Lung Cancer.
P2860
Q33737740-3CB3EA2A-A9DA-4102-B1C8-906713BF024FQ36602123-C309DE92-72EC-43A3-BE86-E011569E0EA2Q37558197-56A85280-7664-459C-B3EC-EE02B6FD2B76Q38635505-97D3598E-EDB2-4700-AEAD-14EB10AB8D5EQ38725429-F5DE20A8-036A-4F7F-A5EA-22729D10461AQ47934716-7126F767-EE7C-442C-9405-7FA3B6E72775Q51643720-2E6544DB-1107-437B-BB40-E087746C1C9B
P2860
Developing biomarker-specific end points in lung cancer clinical trials.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Developing biomarker-specific end points in lung cancer clinical trials.
@en
type
label
Developing biomarker-specific end points in lung cancer clinical trials.
@en
prefLabel
Developing biomarker-specific end points in lung cancer clinical trials.
@en
P2093
P2860
P1476
Developing biomarker-specific end points in lung cancer clinical trials.
@en
P2093
Alice T Shaw
Joel W Neal
Justin F Gainor
P2860
P304
P356
10.1038/NRCLINONC.2014.222
P407
P577
2014-12-23T00:00:00Z